Combination ARV prophylaxis for PMTCT- feasibility and outcomes
Summary: According to the latest Tanzanian guidelines for the prevention of mother-to-child transmission (PMTCT) of HIV, administration of nevirapine single-dose should be the absolute minimum measure. Whenever possible it should be replaced by a combination prophylaxis regimen using a long course of AZT starting in pregnancy week 28.
You are here:
The rationale of this research is to thoroughly monitor the uptake and the outcome of the new combination prophylaxis regimen, and to detect and analyse potential advantages and disadvantages under routine, real life conditions. The study is conducted at the Kyela District Hospital and all HIV positive women in ANC and maternity are eligible after having given informed consent and agreed to sample collection and follow-up visits. Between September 2008 and September 2009, a cohort of around 160 mother-child pairs has been established with a longitudinal follow up to quantify adherence to antiretroviral prophylaxis, reasons for incomplete drug intake, direct and indirect costs, rate of hospital deliveries, clinical outcome of mother and newborn, HIV transmission rate, type and frequency of side effects including AZT toxicity and drug resistance.
Project supervision:Prof. Dr. Gundel Harms-Zwingenberger Dr. Julius Sewangi (Principal investigator in Tanzania)
Dr. Andrea Kunz
Prof. Dr. von Wurmb-Schwark, Institute of Legal Medicine, University of Kiel
September 2008- 2010